Curaleaf expands its activities in Europe by acquiring 100% of Four 20 Pharma

Curaleaf completed the acquisition of the remaining shares of Oven 20 Pharma, a major German producer and distributor of medical cannabis.

Announced on April 30, 2026, this transaction gives the American cannabis group full ownership of the company, in which it already held a majority stake. The buyout covers the remaining 45% of Four 20 Pharma, strengthening the company's position in the cannabis market. Curaleaf's position in one of Europe's most strategic markets.

A key player in Germany's medical cannabis ecosystem

Based in Paderborn, Four 20 Pharma has established itself as one of Germany's leading suppliers of medical cannabis. The company combines a culture renowned for its quality, processing to pharmaceutical standards, and a structured distribution network aimed at pharmacies, retirement homes and selected research institutes.

With around 110 employees, Four 20 Pharma occupies a strategic position in the German market where regulatory compliance and traceability remain decisive factors in guaranteeing patient access. Our EU-GMP and GDP certifications give us a competitive edge in an environment where requirements are increasingly stringent, while regularity of supply has become a central issue for doctors and pharmacies alike.

For its part, Curaleaf presents Four 20 Pharma as a key player in Europe's regulated medical sector, highlighting its commitment to patients, scientific rigor and ability to meet the most stringent standards.

For Curaleaf, this acquisition of full control is also a logical step in its industrial development: to further secure its international supply chain. The group claims that the operation reinforces its vertically integrated model, linking its cultivation sites in Portugal and Canada to its distribution capabilities in the German market.

Curaleaf believes that this integration will enable it to strengthen control over production and logistics, developing what it describes as a «quality guarantee from seed to patient». A strategy that illustrates a growing trend in the international industry: major groups are seeking to consolidate certified European assets in order to reduce their dependence on intermediaries and meet ever more demanding pharmaceutical standards.

Since their initial agreement in 2022, Curaleaf and Four 20 Pharma had already worked together to expand patient access, optimize import flows and support several research projects. The group claims that this collaboration has confirmed the relevance of a «data-driven approach» applied to education, culture and new product development.

Leaders underline Europe's long-term potential

Curaleaf CEO, Boris Jordan, said the agreement strengthened the company's European ambitions and reflected confidence in the market's growth potential.

«The completion of this acquisition of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underlines the strategic importance of building high-quality, locally-anchored operations in a market that will continue to grow exponentially,» he said.

Founder and CEO of Four 20 Pharma, Torsten Greif, also welcomed the initiative, describing it as the next step in the international expansion of the company's business model.

«Joining the Curaleaf family as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma,» he said. «We have built this business on an uncompromising commitment to quality, compliance and patient care, values that align perfectly with Curaleaf's international mission.»

Curaleaf has already begun exporting the brand Oven 20 beyond Germany. The group confirms that it has launched Four 20 in the United Kingdom and in Poland, and plans to expand into other regulated markets.

This international roll-out suggests that Curaleaf sees Four 20 Pharma not only as a German distribution center, but also as an evolving European model, based on pharmaceutical standards rather than consumer branding.